2-methyl-6H-thieno[2,3-b]pyrrole-4-carbonitrile

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡咯类
• 英文名称: 2-methyl-6H-thieno[2,3-b]pyrrole-4-carbonitrile
• 化学式: C₈H₆N₂S
• 分子量: 162.21
• InChiKey: WRJIFMVLILRVOO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  67.8
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• FUSED HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL USE THEREOF
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：EP2749562A1

  公开（公告）日：2014-07-02

  The present invention provides compounds useful as agents for the prevention or treatment of a disease associated with abnormal serum uric acid level and the like. The present invention relates to fused heterocyclic derivatives represented by the following formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, or prodrugs thereof, or pharmaceutically acceptable salts thereof. In the formula (I), ring U represents C6-10 aryl or the like; R1 independently represents a hydrogen atom, a hydroxy group, C1-6 alkyl or the like; m represents an integral number from 1 to 2; ring Q represents 5-membered heteroaryl; n represents an integral number from 1 to 3; R2 independently represents a hydrogen atom, a halogen atom, C1-6 alkyl or the like.

  本发明提供了可用于预防或治疗与血清尿酸水平异常有关的疾病等的化合物。 本发明涉及具有黄嘌呤氧化酶抑制活性并可用作预防或治疗与血清尿酸水平异常有关的疾病的制剂的由下式（I）代表的融合杂环衍生物，或其原药，或其药学上可接受的盐。 在式（I）中，环 U 代表 C6-10 芳基或类似物；R1 独立地代表氢原子、羟基、C1-6 烷基或类似物；m 代表 1 至 2 的整数；环 Q 代表 5 元杂芳基；n 代表 1 至 3 的整数；R2 独立地代表氢原子、卤素原子、C1-6 烷基或类似物。